Content Type: Article

  • US Copyright Office Issues Report Addressing Use of Copyrighted Material to Train Generative AI Systems

    US Copyright Office Issues Report Addressing Use of Copyrighted Material to Train Generative AI Systems

    CLIENT ALERT / US POLICY

    US Copyright Office Issues Report Addressing Use of Copyrighted Material to Train Generative AI Systems

    May 30, 2025

    Read time: 9 min

    Key takeaways
    Overview

    Overview

    On May 9, 2025, the US Copyright Office (“USCO”) released a highly anticipated pre-publication version of the third and likely final installment of its Report on Copyright and Artificial Intelligence – Part 3: Generative AI Training (the “Report”).[1]

    The very next day President Trump dismissed the Register of Copyrights and Director of the USCO, Shira Perlmutter – two days after dismissing Carla Hayden, the Librarian of Congress.[2]Perlmutter has since sued President Trump and the acting Librarian of Congress seeking an injunction blocking her removal.[3]

    It is unclear whether Trump’s dismissals (1) were related to the content of the Report (which was critical of some of the arguments advanced by those who favor free use of copyrighted material to train AI models), (2) prompted the unusual pre-publication of the Report or (3) will affect the issuance or content of the final Report.

    Regardless, the Report addresses an unsettled question underlying dozens of pending copyright AI lawsuits: does the use of copyrighted works without permission to develop and deploy generative AI (“GenAI”) models qualify as “fair use?”[4] This is the billion dollar question facing GenAI companies whose business model is predicated on such use.

    For private fund managers and others who are increasingly looking to harness the power of GenAI and navigate the attendant legal risk, the Report is particularly timely.

    While the Report notes that any fair use analysis must be context-specific, it does offer some helpful general guidelines in assessing fair use for GenAI. According to the Report, transformative use and market effects will be the most significant fair use factors that judges will assess in ruling on GenAI companies’ use of copyrighted material. As detailed below, these factors tend to weigh for or against fair use depending on the circumstances – and one federal judge appears poised to rule broadly in favor of fair use for GenAI.

    Ultimately, the Report does not recommend immediate government intervention on fair use or compulsory licensing issues related to GenAI. Instead, it advises allowing the nascent licensing market for GenAI training data to evolve organically. To address potential gaps in data offerings and market inefficiencies, the Report explores alternative mechanisms, including extended collective licensing schemes, which could provide broader and more efficient licensing solutions by aggregating rights on behalf of multiple copyright holders.[5]

    Fair Use Factors

    For private fund managers contemplating using GenAI in their investment process, the Report’s discussion of the fair use factors is worth examining.

    In addressing the first fair use factor (the purpose and character of the use), the Report notes that determining whether an AI output is transformative is context-dependent. Some use cases are clearly permitted, others clearly are not.[6] Of note to private fund managers, using GenAI for noncommercial research or analysis where portions of the copyrighted works are not reproduced in the outputs is, according to the Report, likely to constitute fair use.[7] However, using unlawfully accessed material (via pirated works or by circumventing paywalls) to train a GenAI model that produces unrestricted competing content would not constitute fair use.[8]

    Also of note for private fund managers, the Report highlights that when retrieval-augmented generation (“RAG”) searches[9] summarize the retrieved copyrighted works rather than providing hyperlinks to the original source, such outputs are less likely to be considered transformative and, therefore, may not qualify as fair use.[10]

    In addressing the second factor (the nature of the copyrighted work), the Report notes that any analysis must be context-specific but a fair use finding is less likely if the material used to train the GenAI is “more expressive” or “previously unpublished.”[11]

    In addressing the third factor (the amount and substantiality of the use), the Report concludes that under certain circumstances, use of an entire work may not in fact weigh against fair use.[12]

    In addressing the fourth factor (market effects), which the Supreme Court has designated as “undoubtedly the single most important element of fair use,”[13] the Report identifies several potential harms, including lost sales, lost licensing opportunities, RAG-related substitution and market dilution. Here, the USCO wades into “uncharted territory,”[14] as no court has yet recognized that market dilution can be applied when AI-generated content competes with human-created works.[15] However, the Report argues that while many GenAI applications promise great public benefits, the sheer unprecedented volume of such applications could pose significant harm to the market for copyrighted works.[16] If courts apply this theory of market dilution, rightsholders may be able to block any use that might have a general effect on the market for copyrighted works, even if it doesn’t specifically impact the rightsholder. Further, the Report emphasizes that where licensing options already exist – or are reasonably likely to develop – the loss of licensing opportunities will disfavor fair use.[17]

    Ultimately, the USCO concludes that fair use analysis of GenAI applications must remain on a case-by-case basis, but the first and fourth factors will carry “considerable weight.”[18]

    Licensing

    The Report outlines four general licensing options: voluntary direct licensing, voluntary collective licensing, extended collective licensing (“ECL”) and compulsory licensing.

    1. Voluntary direct licenses are negotiated on a case-by-case basis between individual rightsholders and AI developers.
    2. Voluntary collective licensing agreements typically involve collective management organizations (“CMO”s) that are authorized by multiple rightsholders to negotiate licenses and administer royalty collection and distribution on their behalf.[19]
    3. ECL builds on the voluntary collective agreement model to cover the works of all relevant rightsholders in a particular category – even those who haven’t actually joined the CMO – while providing an opt-out mechanism for non-participant rightsholders to negotiate separately.[20]
    4. Compulsory licensing is a statutory framework that permits use of copyrighted material without the rightsholder’s direct consent, subject to government oversight and often complex rate-setting procedures.[21]

    Voluntary direct and collective licensing markets for GenAI have already emerged, with others in development.[22] Licensing at scale, however, raises several practical concerns including cost structure, impact on model quality and antitrust issues. Licensing large volumes of copyrighted works at market rates could be prohibitively expensive, particularly given the vast datasets required to train modern AI models. Moreover, if models can only be trained on licensed works, the resulting models may be “tainted by bias and inaccuracy.”[23] There are also antitrust concerns that big tech companies could crowd out smaller developers who might not be able to afford to negotiate broad data licenses.[24] The USCO argues these concerns shouldn’t factor into the fair use analysis, and defers to the Department of Justice for guidance (including a possible antitrust exemption) and the Federal Trade Commission for enforcement.[25]

    The Report ultimately advocates for the growth of voluntary licensing regimes for copyrighted works, which can facilitate AI innovation while protecting rightsholders. To support this approach, the Report further argues that ECL could address market inefficiencies without the market risks from “premature” statutory approaches such as compulsory licensing, which may stifle innovation and distort market incentives.[26]

    Litigation

    The Report is already impacting pending copyright AI lawsuits. While the USCO defers to the courts to “weigh the statutory factors together” and calls it impossible to prejudge litigation outcomes,[27] federal courts can and have deferred to the legal interpretations of agencies such as the USCO, depending on their thoroughness, validity and persuasiveness.[28] As no definitive case law exists on the use of copyrighted material for training GenAI,[29] content owners have already jumped on the Report, citing it as supplemental authority in a detailed counter to the fair use defense in two pending cases.[30] Interestingly, in a May 22, 2025 hearing in a federal case against Anthropic PBC in California, Judge William Alsup said he was leaning “toward finding Anthropic PBC violated copyright law when it made initial copies of pirated books, but that its subsequent uses to train their GenAI models qualify as fair use.”[31] Alsup appeared sympathetic to Anthropic’s argument that its use is “transformative in the extreme” but also might make Anthropic pay for its initial use, noting: “I have a hard time seeing that you can commit what is ordinarily a crime, but get exonerated because you end up using it for a transformative use.”[32] Alsup could be the first judge in the nation to rule on fair use in the GenAI context. And if his reasoning on the fair use factors survives appeal and is adopted by other courts, it could augur well for developers of GenAI, even if the Report itself provides litigation ammunition for content owners.

    Takeaways

    Overall, the Report provides some instructive – if not legally binding – guidance for AI companies, copyright owners and private fund managers.

    For AI companies and downstream users, the Report suggests that implementing effective guardrails to prevent infringing outputs will weigh in favor of fair use and recommends leveraging existing and emerging data licensing frameworks to train AI models. The Report also flags for AI companies that knowingly training AI models on pirated datasets would almost certainly exceed the boundaries of fair use.[33] In such cases, and possibly others, courts may be less inclined to accept arguments about transformative use or net societal benefits of GenAI – particularly when such use poses foreseeable market harm to content owners.[34]

    For copyright owners, the Report encourages creators to pursue organized approaches to collective licensing via CMOs while recognizing market dilution as a potential harm from unrestrained AI training. The Report also notes that copyright owners ideally shouldn’t be required to opt out of the use of their material for training AI models.

    For private fund managers, the Report offers some guidance that certain non-commercial research uses of GenAI may constitute fair use but that other uses (RAG searches) may not, and therefore carry greater risk. Given the volatility at the Copyright Office and the rapid technological and legal developments in the AI space, private fund managers who use GenAI should continue to pay close attention to this area.

    Authored by and Steven Appel.

    If you have any questions concerning this Alert, please contact your attorney or one of the authors.

    In depth
    Authors

    Scott M. Kareff

    Special Counsel

    New York – 919 Third Avenue

    More insights

  • CMS Requests Hospitals Submit Gender-Affirming Care Data

    CMS Requests Hospitals Submit Gender-Affirming Care Data

    ARTICLE / US POLICY

    CMS Requests Hospitals Submit Gender-Affirming Care Data

    May 29, 2025

    Read time: 2 min

    Key takeaways
    Overview

    On May 28, 2025, the Centers for Medicare & Medicaid Services (CMS) sent a letter to “select hospitals” that provide gender-affirming care services, requesting information about how those hospitals adhere to quality standards regarding medical interventions for gender dysphoria in minors, as well as financial data for gender-affirming care procedures provided at the hospitals and paid, in whole or in part, by the federal government.

    CMS likely considers the request to be within its authority to enforce Medicare and Medicaid conditions of participation as evidenced by the letter’s reference to CMS’s “obligation to ensure baseline quality standards.” CMS also cites previous Trump administration actions regarding gender-affirming care for minors as support for the request, including the original executive order, a report from the US Department of Health and Human Services (HHS) reviewing best practices for gender dysphoria treatment (GAC report), and a quality and safety special alert memo for hospitals. Despite these actions, no statutory or regulatory changes to hospitals’ ability to continue providing gender-affirming care services have been promulgated to date. As a result, the letter raises several questions, such as those outlined in this FAQs document.

    In depth

    For information on the recent United States v. Skrmetti decision, download our related FAQs document which outline key takeaways for providers, hospitals, health systems, health plans, and employer plan sponsors who are navigating the implications of the ruling.

    Authors

    Travis Jackson

    Partner

    Los Angeles

    More insights

  • Key Takeaways | How I Learned To Stop Worrying and Love Choppy Waters

    Key Takeaways | How I Learned To Stop Worrying and Love Choppy Waters

    ARTICLE

    Key Takeaways | How I Learned To Stop Worrying and Love Choppy Waters

    May 29, 2025

    Read time: 3 min

    Key takeaways
    Overview

    During this session, panelists that focus on special situations and distressed debt in various sectors provided their insights on the current state of the financial market, recent restructuring trends, and tools to implement when faced with a distressed situation.

    Session panelists:

    • Eugene Fialkovskiy, Managing Director, King Street Capital Management
    • Richard Klein, Senior Managing Director, Hilco Corporate Finance
    • Dave Smith, Managing Director, Legacy Corporate Lending
    • Laurel Wittman, Managing Director, Head of Special Situations, Oxford Finance
    • Moderator: Kristin Going, Partner, McDermott Will & Emery
    In depth
    • Rising Defaults Amid Economic Pressures May Continue Given Market Volatility
      • Last year, a notable increase in defaults emerged, primarily because of interest rate pressure.
      • Although borrowers have largely absorbed that pressure, the impact of tariffs has created new uncertainty.
      • These factors have contributed to heightened market volatility, prompting closer scrutiny of debt markets.
    • Shifting Dynamics in Credit Enforcement
      • Traditional enforcement mechanisms have been weakened because of a lack of covenants in credit agreements, limiting the tools available to lenders.
      • Private credit is becoming increasingly influential, reshaping the market by offering alternative funding and restructuring options.
      • Coupled with the rise of private credit, the market has split between those managing distressed assets internally and those leveraging new avenues to offload risk.
      • Unlike in the past, where lenders had to work through troubled credits, today’s environment offers exit strategies and secondary market solutions.
    • Earlier Engagement and Speed Have Become Defining Characteristics
      • More stakeholders are engaging earlier in the process to preserve value and influence outcomes.
      • With earlier engagement, speed has become a defining feature as distressed change-of-control-transaction timelines have been cut in half, reflecting a more agile and opportunistic market.
    Authors

    Kristin K. Going

    Partner

    New York – One Vanderbilt Avenue

    Samantha R. Koplik

    Partner

    New York – One Vanderbilt Avenue

    Anh B. Lee

    Partner

    Chicago

    Ellen Marie Snare

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • Key Takeaways | Deploying Sponsor Capital: Tactical Financing Moves for Portfolio Companies

    Key Takeaways | Deploying Sponsor Capital: Tactical Financing Moves for Portfolio Companies

    ARTICLE

    Key Takeaways | Deploying Sponsor Capital: Tactical Financing Moves for Portfolio Companies

    May 29, 2025

    Read time: 3 min

    Key takeaways
    Overview

    During this session, the panelists explored whether portfolio company support should come from the sponsor or lenders when portfolio companies require additional funding. They discussed when to deploy sponsor-backed financing solutions and when it may be more advantageous to seek lender-driven alternatives. They also provided their insights on structuring, negotiation tactics, and how to navigate the pressures from competing stakeholders to achieve successful outcomes.

    Session panelists:

    • Viravyne Chhim, General Counsel & CCO, MGG Investment Group
    • Afsar Farman-Farmaian, General Counsel, Varagon Capital Partners
    • Jason Snider, Partner, CFO, Gauge Capital
    • Moderator: Anh Lee, Partner, McDermott Will & Emery
    In depth

    Top takeaways included:

    • Equity as an Alternative.
      • During the term of a portfolio company investment, when portfolio companies have working capital or other liquidity needs, sponsors have many levers to pull from. Often, sponsors must decide whether to have the portfolio company take on additional debt financing or support the company through follow-on equity investments.
      • There are many considerations to take into account. One of the most important from the lender’s perspective is managing relationships with sponsor clients. From all parties’ perspectives, it is essential to align interests from the start so all involved parties can avoid misalignment of interests in the capital structure. Lenders are usually eager to provide additional funding for working capital needs if a portfolio company is performing well or if the platform is anticipating add-on acquisitions.
      • Common forms of follow-on equity support include preferred equity, sponsor guaranties, sponsor capital call agreements, and/or a “qualified borrower” line of credit under a sponsor’s subscription facility. For follow-on equity investments, not only is a sponsor’s role and/or fund economics a consideration but sponsors also must consider the position of their co-investors. Investors who are considering providing liquidity for working capital require incentives to fund those operational needs.
    • An Increase in NAV Lending.
      • The panelists’ recent experiences and a poll of Finance Strategies Forum attendees suggest that “net asset value” (NAV) facilities are becoming a more popular financing option for funds given the flexibility fund borrowers have in structuring these types of facilities.
      • NAV facilities are more common later in a fund’s lifecycle as unfunded capital commitments wind down, but the need for capital continues to grow to further portfolio company investments.
      • For this later stage of portfolio company investment, NAV facilities present a promising option for financing ongoing capital needs since borrowers and lenders can be creative in negotiating economic terms and collateral packages.
    Authors

    Kristin K. Going

    Partner

    New York – One Vanderbilt Avenue

    Samantha R. Koplik

    Partner

    New York – One Vanderbilt Avenue

    Anh B. Lee

    Partner

    Chicago

    Ellen Marie Snare

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • Key Takeaways | Sponsor-Led Syndications: How To Get From a Grid to a Club

    Key Takeaways | Sponsor-Led Syndications: How To Get From a Grid to a Club

    ARTICLE

    Key Takeaways | Sponsor-Led Syndications: How To Get From a Grid to a Club

    May 29, 2025

    Read time: 4 min

    Key takeaways
    Overview

    During this session, the panelists discussed key considerations for selecting and managing lenders ahead of participating in a debt syndicate, including how to evaluate potential lenders, compare key terms, and choose club members for a given transaction.

    Session panelists:

    • David Muckey, Director, Martis Capital
    • Bradley Patton, Managing Director, Capital Markets, Audax Private Debt
    • Dave Welinsky, Managing Director, Capital Markets, Gemspring Capital
    • Matt Zikaras, Managing Director, MidCap Financial
    • Moderator: Ellen Snare, Partner, McDermott Will & Emery
    In depth

    Top takeaways included:

    • When managing both complex deal scenarios and broader economic uncertainties, such as the impact of tariffs, strong relationships are essential. Sponsors often lean on relationship lenders and vice versa, and it is critical to be able to engage in candid discussions on priority points with a trusted counterparty.
    • Sponsors should consider the following when selecting lending partners:
      • The investment thesis. Over the last several years, many sponsors have bolstered existing platforms with add-on acquisitions. If a sponsor is pursuing a roll-up strategy, it should assess the lender group’s willingness and capacity to support future acquisitions with additional financing.
      • A strong foot forward. Sponsors often award allocations (and titles) to lenders who are quick to offer the most favorable terms and commit to the largest holds. A thoughtful and prompt grid response is a positive sign to the sponsor that the parties’ interests are aligned and that future negotiations will be efficient and reasonable.
      • The level of enthusiasm. Sponsors value the effort and enthusiasm demonstrated by potential lenders through a deal process. Often, even if a lender is not selected to lead a deal, the sponsor may recognize the resources committed and the energy invested by a potential lender and, in turn, ensure that the lender is included in the club or given a first look at a future deal.
      • Club dynamics. Lender groups that have a proven track record of effective collaboration bring added stability and productivity to a financing. Sponsors must always consider club dynamics and often prefer to work with lenders who have collectively navigated prior deal processes with ease and efficiency. Sponsors should consider the following when selecting lending partners:
    • Lenders can form new relationships with sponsors by:
      • Focusing on what matters. Prioritize negotiations on terms that move the needle rather than holding out for minor wins on less impactful points. Offering more sponsor-favorable baskets in exchange for solid liability management transaction protections is typically a very smart trade – and one that sponsors notice.
      • Tailoring proposals. Adapt your proposals to align with the sponsor’s strategic objectives for the deal at hand. Whether it’s a roll-up strategy or a heavy cap ex business, showing an understanding of the sponsor’s unique goals and priorities can significantly enhance a lender’s appeal.
      • Being flexible on holds and titles. In the early stages of a relationship, consider reducing minimum hold sizes and foregoing title designations in favor of building trust and establishing longer-term goals. Sponsors recognize when lenders are willing to employ a “big picture” approach and be flexible with general institutional preferences.
    Authors

    Kristin K. Going

    Partner

    New York – One Vanderbilt Avenue

    Samantha R. Koplik

    Partner

    New York – One Vanderbilt Avenue

    Anh B. Lee

    Partner

    Chicago

    Ellen Marie Snare

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • McDermott HealthEx 2025: McKinsey Key Takeaways

    McDermott HealthEx 2025: McKinsey Key Takeaways

    ARTICLE

    McDermott HealthEx 2025: McKinsey Key Takeaways

    May 2025

    Read time: 3 min

    Key takeaways
    Overview

    McDermott HealthEx convened more than 1,300 of the most influential leaders in healthcare and life sciences. The event emphasized creativity, transformation, and growth, with sessions dedicated to innovation, AI-powered partnerships, value-based care, and financial performance, among other topics.

    McKinsey & Company was the official knowledge partner for the inaugural McDermott HealthEx, providing insights into market trends for stakeholders across the value chain. Post-event, McKinsey and McDermott summarized key takeaways from the conversations speakers and attendees had on the ground.

    Key Takeaways

    Healthcare firms across the entire value chain are responding to uncertainty with innovation.

    • Regulatory changes: In the face of shifting regulatory policy affecting topics ranging from Medicaid funding to drug pricing, organizations are turning to breakthrough innovations, new business models, and other opportunities to dramatically improve performance (e.g., monetization of existing services, technology- and AI-enabled care delivery).
    • Macroeconomic and trade fluctuations: Healthcare and life sciences organizations are also looking for creative solutions that can help them prepare for and navigate geopolitical and macroeconomic challenges. This includes conversations around redesigning value chains, to ensure that patients have access to the supplies, services and treatments they need.

    Investors continue to prioritize value creation across assets, even in today’s uncertain dealmaking environment, focusing on ways to develop scale in existing geographies and markets.

    • Core market focus for providers: Providers are doubling down on existing locations and markets to create efficiencies at scale.
    • Technology and AI: Firms across the spectrum are using large-scale data and advanced AI tools to drive value creation opportunities. For example, one hot topic of conversation at McDermott HealthEx was tech-enablement of care workflows.

    Stakeholders across the value chain are innovating in care delivery, customer experience and payment models.

    • Payer strategies: Payers are deploying innovative solutions (e.g., value-based and at-risk payment models for vendors) in response to existing macroeconomic and regulatory pressures, which are creating an environment where providers and services firms are asked to drive value while pursuing efforts to lower the overall cost of care while maintaining quality, safety and access to care.
    • Pharma services players are innovating in their go-to-market strategies to bring solutions to their customer base and strengthen relationships.
    • Generational influence: Millennial decision-makers are demanding more streamlined, consumer-oriented care experiences, driving healthcare firms toward more tech-enabled care delivery, flexible payment models.
    In depth
    Authors
    More insights

  • En Banc Federal Circuit Cools Damages Award Because of Improper Expert Testimony

    En Banc Federal Circuit Cools Damages Award Because of Improper Expert Testimony

    ARTICLE / CLIENT ALERT

    En Banc Federal Circuit Cools Damages Award Because of Improper Expert Testimony

    May 28, 2025

    Read time: 6 min

    Key takeaways
    Overview

    In an en banc decision in EcoFactor, Inc. v. Google LLC, the US Court of Appeals for the Federal Circuit concluded that the district court abused its discretion by admitting testimony from a damages expert that a lump-sum payment in EcoFactor’s license agreements reflected a certain per-unit royalty rate because the testimony was not based on sufficient facts or data.

    In depth

    EcoFactor sued Google over its Nest thermostats that allegedly infringed EcoFactor’s HVAC patent. A prior Federal Circuit panel decision upheld a district court’s denial of the defendant’s motion for a new trial on damages. There, the Federal Circuit found that the plaintiff’s damages expert sufficiently showed that prior license agreements were economically comparable to a hypothetically negotiated agreement between the parties. The Court subsequently issued a decision vacating that panel decision and granting Google’s petition for rehearing en banc to reconsider the practice of using a patent owner’s prior license agreements to determine royalty rates, particularly when the scope of licenses varies or when lump sums and royalties are not clearly apportioned.

    Google argued that the district court abused its discretion in denying a new trial on damages because EcoFactor’s expert opinion was unreliable under Federal Rule of Evidence 702 and Daubert. To estimate a reasonable royalty, the expert employed the hypothetical negotiation framework, which “attempts to ascertain the royalty upon which the parties would have agreed had they successfully negotiated an agreement just before infringement began.”

    As part of his analysis, the expert considered lump-sum settlement licenses between EcoFactor and three licensees: Daikin Industries, Schneider Electric USA, and Johnson Controls. The expert testified that lump-sum amounts in these licenses reflected an $X per unit rate applied to their sales and that Google should pay that same rate.

    In an 8 – 2 decision, the Federal Circuit held that the existing licenses upon which the expert relied were insufficient, individually or in combination, to support the conclusion that prior licensees agreed to the $X royalty rate and, therefore, the district court abused its discretion by failing to exclude this testimony. The Court considered each of the licenses in turn.

    Starting with the Daikin license, the Federal Circuit noted that the agreement contained a preliminary recital, which states that EcoFactor represents it has agreed that the payment set forth in the agreement is based on what EcoFactor believes is a reasonable royalty calculation of $X per unit but that the rate does not appear anywhere else in the license. The Court also noted that the operative payment provision in the agreement states that “[s]uch [a lump-sum] amount is not based upon sales and does not reflect or constitute a royalty.” The Court found that the license directly contradicts any claim that the lump sum is based on any particular royalty rate or even that it is based on sales volume.

    Turning to the Schneider license, the Federal Circuit noted that the agreement contained similar language indicating that EcoFactor represented that the payment set forth in the agreement is based on what EcoFactor believes is a reasonable royalty calculation of $X per unit. However, the Court also noted that the agreement included language indicating that Schneider did not agree that $X per unit is a reasonable royalty. Like the Daikin agreement, the Scheider agreement includes an operative payment provision that states that the lump-sum amount is not based on sales and does not reflect or constitute a royalty. The Court found that while the license could be used as evidence of what EcoFactor might agree to as a royalty rate, it cannot be read to support the expert’s testimony about what Schneider was willing to pay.

    The Federal Circuit noted that the Johnson Controls license contained substantially the same preliminary recital as the Daikin license, finding that this language indicates EcoFactor’s representation of its unilateral belief that $X constitutes a reasonable royalty but does not provide a basis for the expert to conclude that Johnson Controls agreed to that rate.

    The Federal Circuit did, however, state that the licenses are relevant to a reasonable royalty analysis because they state EcoFactor’s belief that $X is a reasonable royalty for its patent portfolio and could be relied upon as an indication of the amount that EcoFactor would have accepted as a willing licensor. EcoFactor’s expert opined that the unilateral assertion in each license’s “whereas” recital evidenced the licensees’ agreement to pay the $X royalty rate. The Court found that the expert’s assertion – that those prior willing licensees had agreed to the $X royalty rate – was not supported by the licenses. Accordingly, the Federal Circuit found that the district court erred in admitting that testimony.

    Apart from the licenses, the only other evidence relied upon by the expert was testimony from EcoFactor’s CEO about how lump-sum license payments were calculated. However, that testimony was not supported by record evidence, given that the CEO testified that neither he nor anyone else at EcoFactor had been given access to sales data for Daikin, Schneider, or Johnson Controls. The expert similarly testified that he had not seen any licensee sales data or documentation regarding calculation of the lump-sum license payments. Instead, he relied on the CEO’s testimony that the calculations were based on the $X per unit rate. The Federal Circuit found that the CEO’s testimony amounted to an unsupported assertion on behalf of EcoFactor that the $X rate was applied to calculate the lump-sum payment amounts. The Court, therefore, determined that this testimony did not provide a sufficient basis for the expert to conclude that Daikin, Schneider, and Johnson Controls agreed to pay a royalty of $X per unit.

    The Federal Circuit concluded that the district court’s decision to admit the testimony was undoubtedly prejudicial, noting that the $X rate was crucial to the expert’s damages analysis since it was both the starting point and the outcome of a hypothetical negotiation between EcoFactor and Google.

    Judge Jimmie Reyna filed a partial dissent, finding that there was ample support for the expert’s testimony, including the CEO’s testimony about his own general understanding of the space and market, the value of the product, consultation with advisors, and undisputed market share data.

    Judge Leonard Stark also filed a partial dissent, finding that, rather than addressing the proper standard for admitting expert testimony under Rule 702 and Daubert, the Federal Circuit’s holding is so narrow that it has no applicability beyond this case.

    Authors

    Amol Parikh

    Partner

    Chicago

    Jodi Benassi

    Partner

    San Francisco

    Paul Devinsky

    Senior Counsel

    Washington, DC

    More insights

  • FAQs for Healthcare Entities Navigating Rights of Conscience Refusals

    FAQs for Healthcare Entities Navigating Rights of Conscience Refusals

    FAQS / US POLICY

    FAQs for Healthcare Entities Navigating Rights of Conscience Refusals

    May 27, 2025

    Read time: 2 min

    Key takeaways
    Overview

    The US Department of Health and Human Services (HHS) Office for Civil Rights (OCR) recently opened a compliance review of a hospital based on a complaint that an ultrasound technician faced potential termination due to a refusal to conduct ultrasounds for abortion procedures. In its announcement of the investigation, OCR stated that “health care professionals should not be coerced into, fired for, or driven out of the profession for declining to perform procedures that Federal law says they do not have to perform based on their religious beliefs or moral convictions.” This is the second such investigation that OCR has initiated in 2025, following an investigation into an alleged termination of a nurse who requested religious accommodation to avoid administering puberty blockers and hormones to minors seeking gender-affirming care.

    In light of these investigations and in recognition of Executive Order 14291, which was signed by US President Donald Trump on May 1, 2025, and establishes the Religious Liberty Commission, hospitals, health systems, and healthcare providers may wish to revisit our prior guidance and webinars while dusting off their policies and procedures related to rights of conscience and requests for religious accommodations. This resource outlines key questions to keep in mind.

    In depth
    Authors

    Sumaya Noush

    Partner

    Chicago

    More insights

  • Navigating political waves and policy shifts

    Navigating political waves and policy shifts

    ARTICLE

    Navigating political waves and policy shifts

    May 2025

    Read time: 6 min

    Overview

    In April, McDermott gathered more than 100 health and life sciences innovators, investors, business leaders and advisers in Paris for our annual European Health & Life Sciences symposium. With such an esteemed crowd available to share insights and expertise, we took the opportunity to consider some of the more recent developments in US government policy and how political shifts on healthcare policy might impact the sector in the years to come.

    With the new administration beginning to make policy changes from the White House, the impact of a shift in approach to US health and life sciences oversight was a hot topic across the symposium agenda. “The US policy environment is incredibly dynamic right now,” says McDermott partner James Ravitz. “The pace of change is unlike that of previous administrations, with the speed at which the new president seeks to move representing a paradigm shift.”

    In depth

    Food and Drug Administration cuts

    One of the most notable impacts of the new administration has been the establishment of the Department of Government Efficiency, which has significantly cut staffing at the Food and Drug Administration (FDA) as part of its cost-saving agenda.

    While the new FDA commissioner Martin Makary has insisted that funding cuts will not impact the agency’s core staff, who are tasked with overseeing the approval and regulation of drugs and devices in the US, the moves have created some uncertainty. The cuts are concentrated in the communications, IT, legislative and policy teams rather than inspectors and review staff, so the agency continues to prioritise faster drug approvals, he has said.

    With a significant number of staff cuts also taking place across the US Department of Health and Human Services (HHS), of which the FDA is one part, to reduce employees from 82,000 to 62,000, we can certainly look forward to a period of consolidation as the dust settles around a new structure. A lot of personnel changes will also take time to implement, with Robert F Kennedy now at the helm of the HHS and new heads of offices assuming control throughout the department.

    It is too early to tell how changes within the HHS and FDA will impact reviews, policy and regulation, but the industry should prepare for a more dynamic backdrop as the future direction of the government bodies takes shape.

    The Inflation Reduction Act and drug pricing

    The Inflation Reduction Act (IRA) of 2022 was a federal law introduced by President Biden that included prescription drug reforms aimed at lowering prices for patients. The introduction of the first ever federal drug pricing programme is scheduled for 2026 and President Trump shows no sign of changing course, having himself focused on drug pricing in his first term.

    On April 15, 2025, President Trump signed an executive order on lowering drug prices that set out a raft of new initiatives, with specific implementation deadlines for government agencies over the next year. The EO highlights a focus from the administration on minimising the perceived negative impact of negotiated prices on innovation and streamlining FDA processes for generics and biosimilars.

    One thing to watch moving forward will be how enforcement is handled, given that penalty provisions in the IRA on drug pricing are severe and can be in excess of $100 million. With hospital pricing rules there has been an indication that there may be more enforcement but lower penalties, so it may be that enforcement and oversight of drug pricing rules turns out to be less stringent than first envisaged.

    “The other area to watch is the litigation being brought by drug manufacturers against the IRA provisions,” says McDermott partner Emily Cook. “So far those cases have been largely unsuccessful on procedural rather than substantive grounds. Once we see the impact of the provisions when they come into effect next year, there will be additional avenues for legal challenge.”

    The uncertainty around drug pricing has led to a cooling of the development of drugs that were thought vulnerable to becoming subject to pricing negotiations, but as more clarity has emerged around which drugs will be impacted, we can expect that to ease.

    Speciality pharma

    Despite US efforts to regulate and introduce greater transparency around drug pricing, there remain significant opportunities for businesses to generate meaningful drug revenues. A big area of activity right now is in speciality pharma, namely high-cost drugs that require specialist handling, where we are seeing an increase in prescribing worldwide.

    Within speciality pharma, GLP-1 medications that are being used to treat obesity and diabetes are seeing particular demand growth. As a result of supply chain issues in GLP-1s in the aftermath of Covid, compounding pharmacies took off, offering custom-made versions of the drugs when commercially available versions were hard to source. Those compounders are now leaving the market, with the industry focusing on enhancing the availability of branded drugs for patients and consumers.

    Trade policy discussions

    The Trump administration continues to shape its policy on trade tariffs for US imports, with the pharmaceuticals industry lobbying against threats of major tariffs on imported drugs that might bring to an end years of low-cost global trade in medicines.

    Drugs in the US are among the most expensive in the world and reducing those costs is a key policy priority for the new government, which believes costs are recouped in the US market for drug development around the world.

    We currently observe a wait-and-see attitude towards US tariff policymaking among both investors and companies, but over the long term we can expect disruption to supply chains given the US is such an important market for the entire pharma, biotech and medical device industry.

    There are also signs that a change in risk appetite may emerge among global players as they navigate policy shifts. It is possible that more clinical trials may be run out of Europe in an effort to spread risk, and that funding challenges may be felt more acutely by US biotechs, though it is too early to adequately assess impacts.

    James R. Ravitz

    Partner

    Washington, DC

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    More insights

  • Key aspects of the 2025 coalition agreement from a real estate and tax perspective

    Key aspects of the 2025 coalition agreement from a real estate and tax perspective

    ARTICLE / CLIENT ALERT

    Key aspects of the 2025 coalition agreement from a real estate and tax perspective

    May 26, 2025

    Read time: 2 min

    Key takeaways
    Overview

    With the 2025 coalition agreement, the German government has set ambitious targets for housing construction, tenancy law, municipal housing policy, and the heat transition in the building sector. The focus is on creating new momentum for the housing market, combined with social responsibility and climate protection.

    In depth
    Authors

    Dr. Maximilian Meyer

    Counsel

    Frankfurt

    More insights